GHK-Cu is present in human plasma, saliva, and urine, with concentrations highest during youth and gradually declining with age
A solid grasp of dosing, delivery, and the number of and length of treatments
87 Coric et al have reported that individuals carrying a combination of the GSTM1-null genotype, active GSTT1, low-activity GSTA1, and variant GSTP1 genotypes exhibited a nine-fold increased risk for renal cell carcinoma compared with those with a reference genotype combination
IV administration helps glutathione reach directly into the bloodstream
Remarkably, all 12 patients reported significant improvement in symptoms and none reported adverse effects in the short term
Our topical serum delivers GHK-Cu at a 3% concentration, the same level used in the clinical studies that demonstrated the most pronounced dermal benefits